highlights to my ears

SPACS still popular (which the deal struck with debtors is essentially as SPAC). Marcum still likes SPAC ipo's
-SPACS allow investor discussion under NDA, which I mentionened before might be key for bio
-SPACs getting muchbigger and attract more sophisticated investors

multi prong strategy to raise funds: institutional, broker-dealers, crowdfunding
-institutions have been hesitant due to how a post RegA+ would trade. Now not so much, but sometimes institutional buyers like with Myomo come in immediately after the IPO
-lots of legal gymnastics
-how to do a valuation with so many parties involved is tricky

NYSE American is currently engaging a handful of people looking to RegA+ /uplist including pre-revenue companies

Roth rep doesn't think Reg A+ is good for biotechs because the crowd doesn't get it